French-Belgian-Swiss APL study group
Welcome,         Profile    Billing    Logout  
 12 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fenaux, Pierre
EPO-PRETAR, NCT03223961: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Active, not recruiting
3
124
Europe
EPREX, Epoetin alfa
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes
09/23
10/28
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
3
246
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
11/24
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe, Canada
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
GFM-DACORAL-DLI, NCT04857645 / 2019-003685-40: ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Active, not recruiting
2
57
Europe
ASTX727, Donor Lymphocyte Infusions, DLI
Groupe Francophone des Myelodysplasies, Astex Pharmaceuticals, Inc.
MDS, AML
04/24
04/25
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Terminated
2
66
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
08/24
08/24
NCT04827719: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Active, not recruiting
2
40
Europe
BST-236
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes, Acute Myeloid Leukemia
04/25
04/25
SATISFY, NCT05935202: Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

Not yet recruiting
2
25
Europe
Mitapivat sulfate, AG-348
EuroBloodNet Association
Hereditary Red Blood Cell Disorder (Disorder)
07/25
12/26
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia

Recruiting
2
44
Europe
Venetoclax, ABT-199
Groupe Francophone des Myelodysplasies, AbbVie
Chronic Myeloid Leukemia
02/26
10/28
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Completed
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
GFM, NCT05226455: Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Recruiting
1/2
55
Europe
venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza
Groupe Francophone des Myelodysplasies, AbbVie
MDS, AML
03/26
09/27
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Recruiting
1/2
36
Europe
Onureg + Venetoclax, CC-486 + ABT-199
Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie
Untreated Myelodysplastic Syndrome
11/25
11/28
NCT02938858: French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Recruiting
N/A
400
Europe
Groupe Francophone des Myelodysplasies, Teva Pharmaceuticals USA
Acute Promyelocytic Leukemia
10/20
10/22
NCT04174547: An European Platform for Translational Research in Myelodysplastic Syndromes

Recruiting
N/A
8670
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
09/21
09/22
ENROL, NCT06250595: European Rare Blood Disorders Platform

Recruiting
N/A
37090
Europe
Collection of clinical and laboratory data from EHR.
Hospital Universitari Vall d'Hebron Research Institute, ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases
Anemia, Bone Marrow Failure, Bleeding Disorder, Iron Metabolism Disorders, Myeloma, Lymphoid Neoplasm, Myeloma, Malignant, Leukemia, Anemia, Sickle Cell, Thalassemia, Blood Cancer, Red Cell Membrane and Enzyme Abnormalities
07/37
07/37
GENOMED4ALL, NCT04889729: Improving MDS Classification and Prognosis by AI

Active, not recruiting
N/A
13284
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
12/22
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fenaux, Pierre
EPO-PRETAR, NCT03223961: A Trial Testing Early Vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Active, not recruiting
3
124
Europe
EPREX, Epoetin alfa
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes
09/23
10/28
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
3
246
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
11/24
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe, Canada
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
GFM-DACORAL-DLI, NCT04857645 / 2019-003685-40: ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Active, not recruiting
2
57
Europe
ASTX727, Donor Lymphocyte Infusions, DLI
Groupe Francophone des Myelodysplasies, Astex Pharmaceuticals, Inc.
MDS, AML
04/24
04/25
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Terminated
2
66
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
08/24
08/24
NCT04827719: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Active, not recruiting
2
40
Europe
BST-236
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes, Acute Myeloid Leukemia
04/25
04/25
SATISFY, NCT05935202: Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

Not yet recruiting
2
25
Europe
Mitapivat sulfate, AG-348
EuroBloodNet Association
Hereditary Red Blood Cell Disorder (Disorder)
07/25
12/26
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia

Recruiting
2
44
Europe
Venetoclax, ABT-199
Groupe Francophone des Myelodysplasies, AbbVie
Chronic Myeloid Leukemia
02/26
10/28
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Completed
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
GFM, NCT05226455: Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Recruiting
1/2
55
Europe
venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza
Groupe Francophone des Myelodysplasies, AbbVie
MDS, AML
03/26
09/27
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Recruiting
1/2
36
Europe
Onureg + Venetoclax, CC-486 + ABT-199
Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie
Untreated Myelodysplastic Syndrome
11/25
11/28
NCT02938858: French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Recruiting
N/A
400
Europe
Groupe Francophone des Myelodysplasies, Teva Pharmaceuticals USA
Acute Promyelocytic Leukemia
10/20
10/22
NCT04174547: An European Platform for Translational Research in Myelodysplastic Syndromes

Recruiting
N/A
8670
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
09/21
09/22
ENROL, NCT06250595: European Rare Blood Disorders Platform

Recruiting
N/A
37090
Europe
Collection of clinical and laboratory data from EHR.
Hospital Universitari Vall d'Hebron Research Institute, ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases
Anemia, Bone Marrow Failure, Bleeding Disorder, Iron Metabolism Disorders, Myeloma, Lymphoid Neoplasm, Myeloma, Malignant, Leukemia, Anemia, Sickle Cell, Thalassemia, Blood Cancer, Red Cell Membrane and Enzyme Abnormalities
07/37
07/37
GENOMED4ALL, NCT04889729: Improving MDS Classification and Prognosis by AI

Active, not recruiting
N/A
13284
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
12/22
12/24

Download Options